Michael R. Nelson

NanoInk, Inc. is an emerging growth technology company specializing in nanometer-scale manufacturing and applications development for the life sciences, engineering, pharmaceutical, and education industries. Using Dip Pen Nanolithography® (DPN®), a patented and proprietary nanofabrication technology, scientists are enabled to rapidly and easily create micro-and nanoscale structures from a variety of materials on a range of substrates. This low cost, easy to use and scalable technique brings sophisticated nanofabrication to the laboratory desktop. Headquartered in the Illinois Science + Technology Park, north of Chicago, NanoInk currently has over 250 patents and applications filed worldwide and licensing agreements with Northwestern University, Stanford University, University of Strathclyde, University of Liverpool, California Institute of Technology and the University of Illinois at Urbana-Champaign.

CytoCore, Inc. develops, manufactures and sells an integrated family of products for the detection, diagnosis and treatment of cancer. The company markets its products under the trade name CytoCore Solutions, which is intended to address sample collection, specimen preparation, specimen evaluation, including detection/screening and diagnosis, treatment and patient monitoring within vertical markets related to specific cancers. The company also designs, markets and sells a companion product to detect breast cancer. It intends to focus on the expansion of its products for the treatment of gynecological cancer as well as bladder, lung, and breast cancers amongst others. CytoCore was founded in December 1998 and is headquartered in Chicago, IL.